These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 30245481)

  • 1. Measles: a disease often forgotten but not gone.
    Leung AK; Hon KL; Leong KF; Sergi CM
    Hong Kong Med J; 2018 Oct; 24(5):512-520. PubMed ID: 30245481
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rubella (German measles) revisited.
    Leung AKC; Hon KL; Leong KF
    Hong Kong Med J; 2019 Apr; 25(2):134-141. PubMed ID: 30967519
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Subacute sclerosing panencephalitis should be eliminated by measles vaccination.
    Liu WL; He ZX; Li F; He D; Ai R
    Hum Vaccin Immunother; 2017 Sep; 13(9):2038-2040. PubMed ID: 28750182
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention of measles, rubella, congenital rubella syndrome, and mumps, 2013: summary recommendations of the Advisory Committee on Immunization Practices (ACIP).
    McLean HQ; Fiebelkorn AP; Temte JL; Wallace GS;
    MMWR Recomm Rep; 2013 Jun; 62(RR-04):1-34. PubMed ID: 23760231
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Antibody persistence following on different vaccination strategies of domestic measles, mumps and rubella combined attenuated live vaccine: a 3-year follow-up study].
    He HQ; Li Q; Yan R; Zhou Y; Tang XW; Deng X; Xie SY; Chen ZP
    Zhonghua Yu Fang Yi Xue Za Zhi; 2017 Apr; 51(4):336-340. PubMed ID: 28395468
    [No Abstract]   [Full Text] [Related]  

  • 6. A new combination vaccine for measles, mumps, rubella and varicella.
    Zareba G
    Drugs Today (Barc); 2006 May; 42(5):321-9. PubMed ID: 16801995
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of combination measles, mumps, rubella, and varicella vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Marin M; Broder KR; Temte JL; Snider DE; Seward JF;
    MMWR Recomm Rep; 2010 May; 59(RR-3):1-12. PubMed ID: 20448530
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of potentially common adverse events associated with the first and second doses of measles-mumps-rubella vaccine.
    LeBaron CW; Bi D; Sullivan BJ; Beck C; Gargiullo P
    Pediatrics; 2006 Oct; 118(4):1422-30. PubMed ID: 17015532
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Measles, mumps and rubella: control by vaccination.
    van Druten JA; de Boo T; Plantinga AD
    Dev Biol Stand; 1986; 65():53-63. PubMed ID: 3556777
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The active offering of measles, rubella and mumps vaccine in new mothers: the experience of health facilities in one of the Local Health Unit of Rome, Lazio, Italy].
    Santoro V; Pettinicchio V; Lancia A; Vazzoler C; De Luca F; Franco E
    Ig Sanita Pubbl; 2016; 72(6):589-597. PubMed ID: 28214912
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Measles, mumps, and rubella antibody patterns of persistence and rate of decline following the second dose of the MMR vaccine.
    Seagle EE; Bednarczyk RA; Hill T; Fiebelkorn AP; Hickman CJ; Icenogle JP; Belongia EA; McLean HQ
    Vaccine; 2018 Feb; 36(6):818-826. PubMed ID: 29317117
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Measles].
    Stock I
    Med Monatsschr Pharm; 2009 Apr; 32(4):118-26; quiz 127-8. PubMed ID: 19445268
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Similar Antibody Levels in 3-Year-Old Children Vaccinated Against Measles, Mumps, and Rubella at the Age of 12 Months or 18 Months.
    Kontio M; Palmu AA; Syrjänen RK; Lahdenkari M; Ruokokoski E; Davidkin I; Vaarala O; Melin M
    J Infect Dis; 2016 Jun; 213(12):2005-13. PubMed ID: 26908733
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Measles 50 Years After Use of Measles Vaccine.
    Goodson JL; Seward JF
    Infect Dis Clin North Am; 2015 Dec; 29(4):725-43. PubMed ID: 26610423
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased measles-mumps-rubella (MMR) vaccine uptake in the context of a targeted immunisation campaign during a measles outbreak in a vaccine-reluctant community in England.
    Le Menach A; Boxall N; Amirthalingam G; Maddock L; Balasegaram S; Mindlin M
    Vaccine; 2014 Feb; 32(10):1147-52. PubMed ID: 24440207
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The epidemiology of subacute sclerosing panencephalitis in England and Wales 1990-2002.
    Miller C; Andrews N; Rush M; Munro H; Jin L; Miller E
    Arch Dis Child; 2004 Dec; 89(12):1145-8. PubMed ID: 15557053
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaccine era measles in an adult.
    Amurao GV; Gottwald LD; Duggan J; Amurao CV; Assaly R
    Cutis; 2000 Nov; 66(5):337-40. PubMed ID: 11107518
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interruption of measles transmission in Gipuzkoa (Basque Country), Spain.
    Cilla G; Basterretxea M; Artieda J; Vicente D; Pérez-Trallero E
    Euro Surveill; 2004 May; 9(5):29-31. PubMed ID: 15208472
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of vaccination with measles-mumps-rubella vaccine at 9, 12, and 15 months of age.
    Redd SC; King GE; Heath JL; Forghani B; Bellini WJ; Markowitz LE
    J Infect Dis; 2004 May; 189 Suppl 1():S116-22. PubMed ID: 15106100
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The elimination of indigenous measles, mumps, and rubella from Finland by a 12-year, two-dose vaccination program.
    Peltola H; Heinonen OP; Valle M; Paunio M; Virtanen M; Karanko V; Cantell K
    N Engl J Med; 1994 Nov; 331(21):1397-402. PubMed ID: 7969278
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.